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Abstract Meningiomas are the second most common prima-
ry tumors affecting the central nervous system. Surgical treat-
ment can be curative in case of complete resection. 5-
aminolevulinic acid (5-ALA) has been established as an intra-
operative tool in malignant glioma surgery. A number of stud-
ies have tried to outline the merits of 5-ALA for the resection
of intracranial meningiomas. In the present paper, we review
the existing literature about the application of 5-ALA as an
intraoperative tool for the resection of intracranial meningio-
mas. PubMed was used as the database for search tasks. We
included articles published in English without limitations re-
garding publication date. Tumor fluorescence can occur in
benignmeningiomas (WHO grade I) as well as inWHO grade
II and WHO grade III meningiomas. Most of the reviewed
studies report fluorescence of the main tumor mass with high
sensitivity and specificity. However, different parts of the
same tumor can present with a different fluorescent pattern
(heterogenic fluorescence). Quantitative probe fluorescence
can be superior, especially in meningiomas with difficult an-
atomical accessibility. However, only one study was able to
consistently correlate resected tissue with histopathological
results and nonspecific fluorescence of healthy brain tissue
remains a confounder. The use of 5-ALA as a tool to guide
resection of intracranial meningiomas remains experimental,
especially in cases with tumor recurrence. The principle of
intraoperative fluorescence as a real-time method to achieve
complete resection is appealing, but the usefulness of 5-ALA
is questionable. 5-ALA in intracranial meningioma surgery
should only be used in a protocolled prospective and long-
term study.
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Introduction
Meningiomas are the second most common primary tumors
affecting the central nervous system, accounting for more than
35 % of the primary brain tumors in adults [1]. The vast
majority of meningiomas are slow-growing, benign (non-
cancerous) tumors, although certain subtypes are more aggres-
sive than others, and benign does not mean that they are with-
out risk. Depending on its size and location, a benign menin-
gioma can cause significant problems to the patient, become
life-threatening, and be extremely difficult to treat.
Originating from the dural covering of the brain, meningiomas
are classified based on the site of origin, the involvement of
adjacent tissues (venous sinuses, bone, brain, and nerves), and
histological grade. The majority of meningiomas fall into his-
topathological classification WHO grade I, whereas atypical
meningiomas (WHO grade II), and malignant or anaplastic
meningiomas (WHO grade III) occur less frequently and con-
stitute approximately 5–7 % of all meningiomas [2]. Being
diagnosed with an intracranial meningioma means a reduction
of life-expectancy to the patient, which is largely caused by
tumor recurrence or outgrowth of tumor remnants,
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irrespective of theWHO grade. Even tumors that are (reported
to be) resected completely may recur, which makes the oper-
ative treatment of every intracranial meningioma a challenge
for the surgeon.
Incompletely resected tumors and high-grade lesions are
frequently additionally treated with fractionated radiotherapy
or stereotactic radiosurgery, and sometimes with hormonal-
and immunotherapy [3–7]. Recurrences that occur after
adjuvant/additional treatment often leave the surgeon with re-
operation as the final and only option left for the patient.
Computer-assisted operative systems (neuronavigation) have
the potential to assist the surgeon in maximizing the extent of
surgical resection, but there are limitations of this technique
due to the phenomenon of Bbrain shift,^ and the absence of
real-time feedback [8–14]. To aid the intraoperative discerning
of tumor from normal brain tissue, dural vessel involvement,
bone invasion, and brain invasive growth, real-time fluores-
cence imaging was introduced, aiming to overcome the afore-
mentioned problems. Although the first attempt of visualizing
brain tumors using a fluorescent dye (fluorescein) was per-
formed in 1948 by Moore and Peyton [15], it took almost
50 years until the principle was applied in a larger surgical
setting [16]. Currently, 5-aminolevulinic acid (5-ALA) is used
to aid intraoperative identification of malignant gliomas [17].
Since its introduction, 5-ALA fluorescence has been applied
in a range of different types of CNS tumors, such as
ependymomas, hemangioblastomas, metastatic brain tumors,
and also in intracranial meningiomas. A number of authors
have tried to outline the merits of 5-ALA in meningioma
surgery, and have published their experience in this field
[18–24], advocating its use in current neurosurgical practice.
Nevertheless, the reliability of 5-ALA in meningioma surgery
has not been established yet. Items such as specificity and
sensitivity have not been solved, and the influences of histo-
pathological grade, previous treatment like radiotherapy, ra-
diosurgery, and medication (steroids, hormonal treatment, and
chemotherapy) on the ability of meningioma cells to produce
fluorescence remain unknown. In this review, we summarize
the reports and clinical studies that have been published about
the application of 5-ALA in intracranial meningioma surgery,
and we report two illustrative cases of our institutional expe-
rience, in order to define the status quo of this technique in
current intracranial meningioma surgery.
5-Aminolevulinic acid
5-Aminolevulinic acid is an indirect fluorophore and a natural
biochemical progenitor of hemoglobin. Administered orally,
5-ALA is resorbed through the upper intestine into the blood,
where it passes the blood–brain barrier [25].
It provokes the synthesis of protoporphyrin IX (PpIX) and
is considered an endogenous photosensitizer. Excited with
fluorescence excitation light (400–440 nm), PpIX emits red
light energy of 635 nm, which is visible for the human eye.
Although 5-ALA accumulates fairly selective in neoplasms,
this process is not entirely tumor-specific as non-malignant
tissue, i.e., brain parenchyma, the subependymal zone, and
choroid plexus also show PpIX accumulation [26–28]. Vice
versa, several studies and our institutional experiences show
that not all tumors or tumor parts become fluorescent with 5-
ALA [18, 20, 21, 23]. Moreover, the degree of heterogeneity




PubMed was used for search tasks, using the key words
Bintracranial meningioma,^ B5-aminolevulinic acid,^ B5-
ALA,^ and Bintraoperative fluorescence-guided resection.^




The literature search identified 11 publications, all in English,
that reported of 5-ALA-assisted intracranial meningioma sur-
gery. These papers are the subject of the present review.
5-ALA fluorescence-guided resection of intracranial
meningiomas in literature
Several studies (n=11) report of 5-ALA-assisted meningioma
surgery. An overview is presented in Table 1.
Kajimoto et al. [18] published the first report about 5-ALA
fluorescence-guided resection in meningiomas in 2007.
Fluorescence-guided resection was performed in 24 non-
consecutive patients revealing 18 benign, 4 atypical, and 2
anaplastic meningiomas. 5-ALA-induced fluorescence had a
sensitivity of 83%with a specificity of 100 %. Interestingly, 3
of 18 (16.7 %) benignmeningiomas and 1 of 4 (25%) atypical
meningiomas did not show fluorescence at all [18].
Intraoperatively, six cases showed 5-ALA fluorescence of
the dura. However, dura infiltration with tumor cells was con-
firmed in five of these cases. In all 24 cases, no strict correla-
tion between cell proliferation and fluorescence pattern was
found. Furthermore, grade of malignancy and fluorescence
intensity were not related. In order to demonstrate the appli-
cability of the 5-ALA technique, the authors illustratively dis-
cuss the case of a gross-total resection of a recurrent large
atypical left convexity meningioma in a 65-year-old patient.
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Exploration for residual tumor was performed using 5-ALA
assistance. In this case, 5-ALA selectively marked tumor tis-
sue, enabling tumor resection with free resection margins and
recurrence-free follow-up until 2.5 years after surgery [18].
Coluccia et al. [20] published the largest series thus far in
2010. They investigated the utility of 5-ALA for the resection
of intracranial meningiomas in 33 consecutive patients.
Histopathological grading revealed 26 benign (WHO grade
I), 6 atypical (WHO grade II), and 1 anaplastic (WHO grade
III) meningioma. The authors report 100 % sensitivity of 5-
ALA fluorescence with a specificity of 94 %. Two cases did
not show any fluorescence. Both were grade I meningiomas
with low proliferation (MIB-1) and mitotic index (MI). In
patients with positive fluorescence, no correlation of fluores-
cence and histopathological grade was found [20]. In 2011,
Morofuji et al. [19] presented the case of an 83-year-old fe-
male patient. Previously obtained data using CT and MRI
revealed a cranium invading, rapidly growing tumor, which
proved to be an atypical meningioma (WHO II). During sur-
gery, a highly fluorescent tumor was seen, whereas the sur-
rounding dura mater appeared to be signal free. Tumor inva-
sion into the diploë to the inner table at the stump of the upper
orbital margin was not detectable with the standard surgical
microscope, but clearly discernable with 5-ALA. The authors
report 100 % correlation of histological results with intraop-
erative findings. They also found a higher accuracy using 5-
ALA-induced fluorescence than contrast enhancement from
previously obtained MRI scans. Consequently, the authors
concluded that 5-ALA-assisted meningioma resection is not
only superior to naked eye evaluation but also has the poten-
tial to accurately distinguish tumor-infiltrated bone and dura
mater from healthy tissue [19].
Whitson et al. [21] report similar results in their case study
of a 53-year-old female patient with a recurrent meningioma,
albeit with slight differences. Initially, a WHO grade II me-
ningioma was resected and the first recurrence was treated
with radiotherapy. Routine follow-up MRI scans indicated
recurrence of what appeared to be a more aggressive neoplasm
along the falx, extending into both frontal lobes. During 5-
ALA-assisted resection, two large nodules were found along
the falx, which showed inhomogeneous fluorescence. Neither
naked eye nor fluorescence evaluation showed involvement of
surrounding brain parenchyma. However, minimal back-
ground fluorescence of uninvolved dura was noticed micro-
scopically. Interestingly, different parts of the tumor signal did
not r ise above background f luorescence levels .
Histopathological evaluation of the tumor discovered a
WHO grade I meningiomawith a very low proliferative index.
Despite of this, the authors concluded that fluorescence yields
a clear delineation of tumor tissue, although histological re-
sults did not correlate with their findings, thus ignoring the
inhomogeneous or even absent fluorescence in certain parts of
the tumor [21].
In 2012, Chae et al. [24] discussed the case of a 69-year-old
male patient with a meningioma in the Sylvian fissure with
strong attachment to the Sylvian vein. Due to the complicated
location of the tumor and involved normal brain structures, 5-
ALA-induced fluorescence was used to achieve resection of
residual tumor tissue and prevent structural damage of the
surrounding tissue. Pathological examination revealed a be-
nign meningioma (WHO I) [24].
Cornelius et al. [30] evaluated 5-ALA and 18F-FET-PETas
metabolic imaging tools for resection of a recurrent olfactory
groove meningioma. Surgery was upon others handicapped
by extensive growth of the tumor in surrounding tissue, delin-
eation of pathological dura, infiltration of bony skull base, and
scarring due to prior surgeries. In the reported case, 5-ALA
fluorescence helped to dissect the adherent interface between
tumor and brain, and to distinguish meningioma tissue from
swollen mucosa and thus enabled straightforward dissection.
However, for intraoperative assessment of bony and dural
infiltration, FET-PETwas used.
A larger study of Cornelius et al. [31] evaluated the impact
of 5-ALA fluorescence-guided surgery on the extent of resec-
tion of meningiomas, with special regard to high-grade tu-
mors. The authors investigated the potential of 5-ALA-
guided surgery for discriminating different WHO grades in-
traoperatively, and analyzed whether fluorescence had an im-
pact on the extent of resection and influenced surgical strategy.
Thirty-one meningioma patients between 2008 and 2014 were
operated using 5-ALA assistance. The investigated group
consisted of 19 WHO grade I, 8 WHO grade II, and 4 WHO
grade III tumors. Seventy-five percent of high-grade meningi-
omas (grades II and III) were recurrences at the time of sur-
gery, of which 58 % had been previously treated with
radiotherapy.
Two cases (grade I) did not show any fluorescence, where-
as 17 cases (14 grade I) showed Blow^ and 12 cases (3 grade I)
Bhigh^ fluorescence. Highly significant correlation between
WHO grade and fluorescence intensity was found. 5-ALA
improved the extent of resection in 19 % of the benign me-
ningiomas and in 75 % of high-grade lesions compared to
white light, especially in infiltrated brain, around brain ves-
sels, and cranial nerves. However, 5-ALA-assisted surgery did
not influence surgical strategy.
Recently, Della Puppa et al. [32] assessed the role of 5-
ALA fluorescence in guiding the resection of bone-invading
meningiomas in 12 patients (8 females and 4males) delivering
98 bone samples. Meningioma tissue as well as bone invasion
showed overall bright fluorescence. Bone invasion was con-
firmed histologically in 100 % of the fluorescent samples.
However, their work showed that non-fluorescent bone can
contain areas of meningioma invasion in approximately
13 % of the investigated cases. Their findings suggest that
hyperostotic bone might influence the sensitivity of 5-ALA
fluorescence. Postoperatively, two cases of non-fluorescent
622 Neurosurg Rev (2015) 38:619–628
hyperostosis were reported, where the existence or absence of
potential residual tumor tissue was indeterminable.
The previous reports [18–21, 24, 30–32] discussed the
qualitative (visual) usefulness of 5-ALA as an intraoperative
imaging tool for the resection of intracranial meningiomas.
The following reports [22, 23, 33] also take the quantitative
protoporphyrin IX concentrations into account.
Valdes et al. [22] compared the sensitivity and specificity of
visual fluorescence of PpIXwith its imperceptible quantitative
concentrations in several brain tumors, using a specially de-
signed probe for intraoperative fluorescence and white light
reflectance measurement. Fourteen patients with low-grade
glioma, high-grade glioma, meningioma, and metastases were
included. Six of these patients harbored WHO grade I or II
meningiomas. Quantitative probe fluorescence in meningio-
mas was associated with a higher sensitivity (99 %) than vi-
sual fluorescence (80 %), with an overall specificity of 93 %
[22].
A more recent study of Valdes et al. [33] evaluated the use
of qualitative and quantitative 5-ALA assistance in 15 menin-
gioma patients. They investigated quantitative fluorescence
levels in ten benign cases highlighting the importance of this
approach in detecting otherwise non-visible but diagnostically
relevant fluorescent levels of PpIX concentrations
(0.010 mg/ml). They detected significant levels of PpIX in
69 % of histologically confirmed instances of tumor tissue
with no visible fluorescence.
Bekelis et al. [23] report of a 52-year-old female patient
with a WHO grade I meningioma with intraorbital invasion.
This study also evaluated qualitative and quantitative fluores-
cence. Qualitative assessment of visible fluorescence was per-
formed using naked eye evaluation. An intraoperative probe
for in situ fluorescence detection was used for quantitative
assessment of varying PpIX concentrations in tumor and
healthy tissue. Intraoperative probe fluorescence yielded
100 % sensitivity and as such proved to be superior to visible
fluorescence, which had a sensitivity of 80 % in detecting
tumor tissue. Furthermore, histopathologically confirmed tu-
mor tissue showed no visible levels of fluorescence but did
accumulate significant PpIX concentrations (>0.10 mg/ml)
[23]. The authors conclude that quantitative fluorescence
using an intraoperative fluorescence probe may be used as
an addition to standard surgical and fluorescence-guided re-
section, especially in meningiomas with difficult surgical ac-
cessibility or heterogeneous fluorescence pattern [22, 23, 33].
This approach could maximize the effect of 5-ALA fluores-
cence guidance while minimizing potential collateral damage.
Illustrative cases from our own institute
A 46-year-old male with a parietal meningioma (WHO grade
I) underwent his first craniotomy in 2002. Due to a regrowth
after 6 years (which at that time it appeared to be a WHO
grade II meningioma), re-craniotomy and stereotactic
Fig. 1 a, b MRI showing the third recurrence of a parasagittal
meningioma with two prominent noduli involving the skin; c, d the
intradural tumor part shows bright 5-ALA fluorescence; e, f the skin
involving tumor noduli also show bright 5-ALA fluorescence 210×
111 mm (72×72 DPI)
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radiosurgery (54 Gy) were performed. In the same year, rou-
tine follow-up showed regrowth with the now also involve-
ment of the cranium. Histopathological analysis revealed an
anaplastic meningioma (WHO grade III). In 2009, the tumor
recurred, showing extracranial (cutaneous) and intracranial
infiltration. Therefore, 5-ALA-assisted tumor resection was
accomplished. Both intra- and extracranial tumor parts (both
WHO grade III) showed bright fluorescence (see Fig. 1). The
patient was additionally treated with stereotactic radiosurgery
(20 Gy). In 2011 and 2012, two re-craniotomies were per-
formed because of tumor growth, not far from the original
operative area, both resulting into the resection of atypical
meningiomas (WHO grade II).
A 65-year-old female with a subtotal resection of an occip-
ital falx meningioma (WHO grade I) in 1986 underwent re-
craniotomy and radiotherapy treatment (60 Gy) in 2004 at our
institution. Histopathological examination revealed an atypi-
cal meningioma (WHO grade II). In 2008, re-craniotomy was
performed following tumor relapse (WHO grade II). Due to a
next recurrence, 5-ALA-assisted surgery was performed in
2010, where the intracranial tumor was fluorescence-
negative (meningioma WHO grade II). The next year, the
tumor recurred, with an extension into the extracranial subcu-
taneous tissues. The intracranial part was compatible with a
WHO grade II meningioma, while the extracranial tumor ex-
tension was consistent with a WHO grade III meningioma. 5-
ALA-assisted resection showed no fluorescence of the
extracranial tumor (WHO III), whereas the intracranial part
(WHO II) showed bright fluorescence (see Fig. 2).
Discussion
In this review, we summarized the application of 5-ALA-
induced fluorescence as an intraoperative tool to maximize
the resection of intracranial meningiomas. Furthermore, we
discussed our institutional experiences with this technique
presenting two illustrative cases.
On aggregate, a total number of 126 patients (not including
our own two cases) with 5-ALA-assisted intracranial menin-
giomas resection are reported. All authors used a modified
surgical microscope for fluorescence-guided visualization of
the tumor and followed the protocol presented by Stummer
et al. for the application of 5-ALA [17]. This protocol was
designed for malignant glioma surgery and validation for me-
ningioma surgery has not been done, as far as we know. We
question the reliability of 5-ALA in intracranial meningioma
surgery. As we showed, histologically identical meningiomas
did not respond equally to 5-ALA administration.
Furthermore, we observed a change in fluorescence response
over time and a variation of fluorescence in different areas of
the same tumor, which might have been caused by the influ-
ence of additional treatment (like radiotherapy or previous
Fig. 2 a, bMRI showing the fourth recurrence of a right sided occipital
falx meningioma with tumor invasion of the skin; c, d intradural tumor
part showing bright 5-ALA fluorescence; e, f subcutaneous tumor tissue
does not show a fluorescent signal under violet-blue light 207×112 mm
(72×72 DPI)
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medical treatment) prior to reoperation of a recurrent
meningioma.
Most studies [18–21, 24, 30–32] reported fluorescence of
the main tumor mass with high sensitivity and specificity. In
the majority of cases, fluorescence did lead to an extension of
the resection and to the removal of additional tumor.
However, only Morofuji et al. [19] were able to consistent-
ly correlate resected tissue with histopathological findings. In
three studies [22, 23, 33], state-of-the-art fluorescence imag-
ing with 5-ALAwas compared to quantitative probe fluores-
cence, resulting in a higher accuracy and sensitivity of the
latter technique. However, the superiority of this approach
above naked-eye evaluation of 5-ALA and its implementation
in the operative routine need further investigation.
In meningioma surgery, there is no ultimate evidence
regarding the appropriate resection margin to minimize
recurrence [34–37]. Fluorescence imaging may help to
more accurately determine whether excision margins are
free of tumor cells. This requires validation of the exact
detection threshold of the current intraoperative tech-
niques. The findings in this review reveal that 5-ALA-
induced fluorescence seems a promising approach for
the detection of (remnant) meningioma cells. However,
it lacks sufficient reliability regarding specificity [18,
21, 33] and histopathological accuracy to establish a
consistent real-time assistance in meningioma surgery.
In some cases, where fluorescence was reported, the
difference between tumor and background fluorescence
is hardly detectable with the naked eye [21, 24].
Our two illustrative cases revealed that tumor fluorescence
under 5-ALA can be inconsistent and inhomogeneous, which
limits the (presumed) benefits of fluorescence-guided surgery
[18, 20, 21, 23, 30–33]. Pfisterer et al. [38] suggest that the
genetic regional heterogeneity, that is often found in meningi-
omas, can be of high prognostic and diagnostic value. This
could be an explanation for the inconsistency in fluorescence.
Another explanation for the unspecific fluorescence pattern
was provided byMasubuchi et al. [28], who demonstrated that
PpIX is quickly excreted by meningioma cells into the extra-
cellular space. Thus, depending on the threshold of the optical
systems, non-malignant tissue might show false-negative
fluorescence.
As stated previously, PpIX emits visible red light energy of
635 nm upon previous excitation. The eyes threshold for de-
tection of this light depends on the retina, and its sensitivity/
specificity for red light from, e.g., inborn retina diseases and
age. These physiological limitations help to understand the
different interpretation in visual fluorescence and emphasize
the necessity for a more objective measurement of fluores-
cence (by quantitative biomarkers). However, even with the
use of quantitative probe, the detection of tumor will depend
on the concentration threshold for PpIX and on the experience
of the surgeon.
In a recently published letter, Wilbers et al. [39] discuss
their experience with an atypical meningioma. Using 5-
ALA-induced fluorescence, the authors have been able to de-
tect residual infiltration of the tumor in the dura and adjacent
brain tissue. This can be essential regarding prognosis, regard-
less of the meningioma type. Moreover, the authors indicate
the potential use of PpIX detection in adjuvant photodynamic
therapy (PDT). This is worthy of further investigation as deep
penetration of visible light (400–750 nm) is impeded, mainly
due to autofluorescence by surrounding tissue and absorption
by hemoglobin.
It is widely known that radiation therapy (RT) of the upper
body, either as a direct effect of treatment or by incidental
exposure, has an etiological effect on the development of brain
tumors. Moreover, it is found that radiation-induced meningi-
omas express more atypical features and multiplicity, com-
pared to non-radiation-induced meningiomas [40–43]. Our
own experience is that recurrent meningiomas that have been
treated with radiotherapy can show alteration in fluorescence.
Most of the studies reviewed do not mention previous radio-
therapy of their patients (see Table 1). However, such infor-
mation is essential for the correct interpretation of 5-ALA-
induced fluorescence. Notably, it is especially this category
of patients (multiple craniotomies and radiotherapy for recur-
rent meningioma) that urges for the development of a tumor-
specific tool to improve intraoperative tumor detection and a
radical resection.
Based upon the above dilemmas, the question is how to
proceed.
It is evident that there is no(t yet a) solid basis for the
reliable application of 5-ALA in meningioma surgery. In our
opinion, 5-ALA-assisted tumor resection should be
protocolled and considered for all patients with primary and
recurrent meningioma. Close and detailed follow-up is need-
ed, also taking into account the complete patient history and
previous medical treatment including radiation therapy and/or
stereotactic surgery. Tumor specimen should be incubated and
cultured, to allow for future tumor cell research and for the
development of a tumor-specific intraoperative fluorescence
techniques, as recently also has been suggested by
Behbahaninia et al. [44].
Targeting of a tumor-specific biomarker with a fluorescent
probe yields a high discrimination ratio between tumor and
healthy tissue and as such, this technique has the potential to
accurately identify tumor deposits and may be useful in the
evaluation of tumor margins. 5-ALA (400–440 nm) operates
in the visible light spectrum (400–750 nm); wavelengths in
which the signal is partly limited by autofluorescence of back-
ground tissue and by absorption by hemoglobin. In contrary,
tumor-specific imaging using fluorescent dyes in the near-
infrared (NIR) range (750–1000 nm) yield better signal-to-
background ratios [45]. Van Dam et al. [46] have successfully
reported tumor-targeted fluorescence imaging in patients with
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ovarian cancer to detect metastatic tumor tissue. In this con-
cept, it is essential to determine which biomarkers are upreg-
ulated most in the tumor cells. Those markers can serve as a
target for a fluorescent imaging agent. Upon excitation by a
laser, the reflected signal by the fluorescent agent can be de-
tected by a sensitive camera system. Thus, identifying
meningioma-specific biomarkers may be a challenging focus
for future investigations. Image-guided resection of meningi-
omas could benefit from this concept. Fluorescent dyes with a
NIR emission wavelength are likely to be more suitable for
intraoperative imaging purposes due to their tumor-specificity.
Thus, a tumor-specific approach would allow a more sensitive
tumor delineation and assessment of tumor margins.
Conclusion
It is challenging to draw definitive conclusions regarding the
role of 5-ALA fluorescence-guided meningioma surgery from
the present review. 5-ALA-assisted resection does not replace
the resection of tumor under white light. Moreover, this new
technique serves as additional information upon the surgeon’s
experience, and his/her tactile and visual perception.
The following is a list of findings, based on our institutional
experiences, and the status quo of this technique in the
literature.
& Tumor cell fluorescence can appear in benign meningio-
mas (WHO grade I) as well as in high-grade lesions
(WHO grade II and III) meningiomas.
& There seems to be no correlation between fluorescence
intensity and proliferation rate (MIB-1 Labeling Index)
or mitotic index (MI).
& Sensitivity and specificity rates vary between studies, but
are generally high.
& Within the same tumor, fluorescence can be very different
(heterogenic fluorescence), showing highly fluorescent
parts, and parts that do not respond at all.
& The fluorescence response to 5-ALA administration in a
recurrent meningioma of the same histological grade can
differ from the response observed during the former resec-
tion, changing from B5-ALA positive^ to B5-ALA nega-
tive,^ or vice versa.
This review shows that 5-ALA, as a tool to guide resection
of intracranial meningiomas, is still very experimental and
should only be used in protocolled prospective studies. The
superiority of 5-ALA-assisted resection of intracranial menin-
giomas regarding progression-free survival needs to be inves-
tigated in prospective cohort studies. However, the principle
of fluorescence as a real-time method to assist the surgeon in
achieving complete resection (and cure!) of benign intracrani-
al tumors is very appealing. Besides, from the application of 5-
ALA, the use of other real-time modalities, especially tumor-
specific intraoperative fluorophores, are very worthy to be
investigated.
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Comments
Kwan Park, Doo-Sik Kong, Seoul, Korea
To date, the use of 5-ALA has been limited to the intra-axial cerebral
neoplasm. This is the first study of review about the usefulness of 5-ALA-
induced fluorescence for the intracranial extra-axial tumors. The authors
reviewed the recent literatures regarding the application and the efficacy
of 5-ALA for intracranial meningiomas in detail and summarized their
experience. According to the authors’ review, they found that 5-ALA can
be efficaciously used under the specific conditions such as recurrent cases
or bone-invading cases. However, through this review, the authors have
still questions about the efficacy of 5-ALA-guided surgery for intracranial
meningiomas because it has heterogenic findings over time and location.
Agreeing to their conclusions, the readers should acknowledge there are
many criticisms about the use of 5-ALA for intracranial meningiomas.
Neurosurg Rev (2015) 38:619–628 627
Hans-Jakob Steiger, Düsseldorf, Germany
On the basis of personal experience with 5-ALA fluorescence
during resection of cranial meningiomas, Motekallemi and coau-
thors reviewed the actual literature regarding the application and
usefulness of the method for meningiomas. Although a number of
studies regarding the issue have been published since 2007, some
questions remain. Though it appears that intensity of fluorescence
correlates with WHO grade, the correlation seems to be less strong
than with astrocytoma. A further open issue is whether more rad-
ical resection can be achieved when using 5-ALA fluorescence.
Long-term studies are necessary to evaluate a possible impact on
recurrence and overall survival.
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